PE20010025A1 - Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumores - Google Patents
Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumoresInfo
- Publication number
- PE20010025A1 PE20010025A1 PE2000000317A PE0003172000A PE20010025A1 PE 20010025 A1 PE20010025 A1 PE 20010025A1 PE 2000000317 A PE2000000317 A PE 2000000317A PE 0003172000 A PE0003172000 A PE 0003172000A PE 20010025 A1 PE20010025 A1 PE 20010025A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- day
- growth factor
- receptor
- ras signaling
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 9
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 230000004611 cancer cell death Effects 0.000 title 1
- 231100000405 induce cancer Toxicity 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 abstract 1
- XYNHQVIVVBWVAG-UHFFFAOYSA-N 4h-cyclohepta[f]quinoline Chemical compound C1=CC=CC=C2C3=CC=CNC3=CC=C21 XYNHQVIVVBWVAG-UHFFFAOYSA-N 0.000 abstract 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 abstract 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 abstract 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 abstract 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004357 Transferases Human genes 0.000 abstract 1
- 108090000992 Transferases Proteins 0.000 abstract 1
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229960002092 busulfan Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960005243 carmustine Drugs 0.000 abstract 1
- 229960004630 chlorambucil Drugs 0.000 abstract 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960000684 cytarabine Drugs 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229960003901 dacarbazine Drugs 0.000 abstract 1
- 229950008696 farnesil Drugs 0.000 abstract 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 abstract 1
- 229960000961 floxuridine Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 229960001101 ifosfamide Drugs 0.000 abstract 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 229960002247 lomustine Drugs 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 229960004961 mechlorethamine Drugs 0.000 abstract 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 abstract 1
- 229960001924 melphalan Drugs 0.000 abstract 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 abstract 1
- 229960001428 mercaptopurine Drugs 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 229960000952 pipobroman Drugs 0.000 abstract 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 abstract 1
- 239000012268 protein inhibitor Substances 0.000 abstract 1
- 229940121649 protein inhibitor Drugs 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 108091006082 receptor inhibitors Proteins 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 229960001052 streptozocin Drugs 0.000 abstract 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229960004964 temozolomide Drugs 0.000 abstract 1
- 229950001353 tretamine Drugs 0.000 abstract 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/289,255 US6316462B1 (en) | 1999-04-09 | 1999-04-09 | Methods of inducing cancer cell death and tumor regression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20010025A1 true PE20010025A1 (es) | 2001-02-05 |
Family
ID=23110723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000000317A PE20010025A1 (es) | 1999-04-09 | 2000-04-07 | Uso de un inhibidor de fpt y un inhibidor de la via de senalizacion ras adicional para inducir la muerte de celulas cancerosas y la regresion de tumores |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6316462B1 (OSRAM) |
| EP (1) | EP1165078B1 (OSRAM) |
| JP (1) | JP2003529540A (OSRAM) |
| CN (1) | CN100421661C (OSRAM) |
| AR (1) | AR023400A1 (OSRAM) |
| AT (1) | ATE347360T1 (OSRAM) |
| AU (1) | AU783177B2 (OSRAM) |
| BR (1) | BR0009670A (OSRAM) |
| CA (1) | CA2364675A1 (OSRAM) |
| CY (1) | CY1107545T1 (OSRAM) |
| DE (1) | DE60032226T2 (OSRAM) |
| DK (1) | DK1165078T3 (OSRAM) |
| ES (1) | ES2275505T3 (OSRAM) |
| HK (1) | HK1038512B (OSRAM) |
| HU (1) | HUP0200773A3 (OSRAM) |
| MX (1) | MXPA01010211A (OSRAM) |
| MY (1) | MY120841A (OSRAM) |
| NO (1) | NO329133B1 (OSRAM) |
| NZ (1) | NZ514628A (OSRAM) |
| PE (1) | PE20010025A1 (OSRAM) |
| PT (1) | PT1165078E (OSRAM) |
| TW (1) | TWI255184B (OSRAM) |
| WO (1) | WO2000061145A1 (OSRAM) |
| ZA (1) | ZA200108258B (OSRAM) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
| US20030064949A1 (en) * | 1998-02-17 | 2003-04-03 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| US20030060434A1 (en) * | 1997-02-18 | 2003-03-27 | Loretta Nielsen | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| AT500848B1 (de) * | 1999-06-25 | 2008-01-15 | Genentech Inc | Humanisierte anti-erbb2-antikörper |
| US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| CA2397657A1 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica Inc. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| DE10017480A1 (de) * | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| EP1280923A2 (en) * | 2000-04-28 | 2003-02-05 | Millennium Pharmaceuticals, Inc. | 14094, a human trypsin family member and uses thereof |
| CN1447696A (zh) | 2000-05-19 | 2003-10-08 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
| US20020077301A1 (en) * | 2000-10-05 | 2002-06-20 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| HK1052870A1 (zh) * | 2000-10-05 | 2003-10-03 | Q. Daley George | 诱导癌细胞死亡和肿瘤消退的方法 |
| EP1353693B1 (en) | 2001-01-16 | 2005-03-16 | Glaxo Group Limited | Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer |
| CA2434308C (en) * | 2001-01-18 | 2010-09-21 | Schering Corporation | Synthesis of temozolomide and analogs |
| NZ516873A (en) * | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
| US6703400B2 (en) | 2001-02-23 | 2004-03-09 | Schering Corporation | Methods for treating multidrug resistance |
| HUP0402401A2 (hu) * | 2001-11-30 | 2005-03-29 | Schering Corp. | Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| EP2324825A1 (en) | 2002-02-11 | 2011-05-25 | Bayer Healthcare LLC | Aryl ureas with angiogenesis inhibiting activity |
| US6984389B2 (en) * | 2002-04-25 | 2006-01-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| AU2003231098A1 (en) | 2002-04-25 | 2003-11-10 | University Of Connecticut Health Center | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality |
| NZ536475A (en) * | 2002-05-24 | 2008-06-30 | Schering Corp | Neutralizing human anti-igfr antibody |
| AU2003287366A1 (en) * | 2002-10-31 | 2004-06-07 | University Of Rochester | Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| US8168568B1 (en) | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
| CA2524305C (en) * | 2003-05-01 | 2015-12-08 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
| DK1663978T3 (da) | 2003-07-23 | 2008-04-07 | Bayer Pharmaceuticals Corp | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser |
| ATE514783T1 (de) | 2003-11-12 | 2011-07-15 | Schering Corp | Plasmidsystem zur expression mehrerer gene |
| JP4691041B2 (ja) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | Ｇｔｐアーゼ阻害剤および使用方法 |
| PE20050928A1 (es) * | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
| JP2007513967A (ja) * | 2003-12-11 | 2007-05-31 | セラヴァンス， インコーポレーテッド | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |
| CA2554779A1 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| DE602005025685D1 (de) * | 2004-12-03 | 2011-02-10 | Schering Corp | Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie |
| ES2710439T3 (es) | 2005-01-21 | 2019-04-25 | Genentech Inc | Dosificación fija de anticuerpos HER |
| KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
| US7524831B2 (en) * | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
| US20060233810A1 (en) * | 2005-04-15 | 2006-10-19 | Yaolin Wang | Methods and compositions for treating or preventing cancer |
| PL2161336T5 (pl) * | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| AU2006259536A1 (en) * | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
| KR101246504B1 (ko) * | 2005-06-17 | 2013-03-26 | 임클론 엘엘씨 | 항－ＰＤＧＦＲα 항체 |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| US9095581B2 (en) | 2005-07-21 | 2015-08-04 | Ardea Biosciences, Inc. | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof |
| AU2006275528B2 (en) | 2005-07-29 | 2012-03-08 | Children's Hospital Medical Center | GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase |
| KR101353706B1 (ko) * | 2006-02-03 | 2014-02-18 | 유니버시티 오브 워싱톤 | 전립선 암 치료용 보강제로서의 ⅰｇｆ-ⅰｒ 길항제 |
| US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
| US20080112888A1 (en) * | 2006-06-30 | 2008-05-15 | Schering Corporation | Igfbp2 biomarker |
| JP2010507659A (ja) * | 2006-10-25 | 2010-03-11 | シェーリング コーポレイション | 卵巣癌を処置する方法 |
| EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
| NZ580982A (en) | 2007-05-08 | 2012-05-25 | Schering Corp | Methods of treatment using intravenous formulations comprising temozolomide |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| CA2690334C (en) | 2007-06-08 | 2017-02-14 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| CA2924418A1 (en) * | 2007-07-30 | 2009-02-05 | Jean-Michel Vernier | Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same |
| US20110129549A1 (en) * | 2008-04-17 | 2011-06-02 | Liu Julie F | Tricyclic benzo[5,6]cyclohepta[1,2-b]pyridine derivatives and uses thereof |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| WO2010025337A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
| US20100098654A1 (en) * | 2008-10-21 | 2010-04-22 | Fabio Pastorino | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| JP5705836B2 (ja) | 2009-05-29 | 2015-04-22 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター |
| KR20130000384A (ko) | 2010-02-18 | 2013-01-02 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 뉴레귤린 길항제 및 암의 치료에서의 그의 용도 |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
| JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
| US20140363438A1 (en) | 2011-08-17 | 2014-12-11 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
| US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
| AU2012346540C1 (en) | 2011-11-30 | 2019-07-04 | Genentech, Inc. | ErbB3 mutations in cancer |
| WO2013083810A1 (en) | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| RU2014136886A (ru) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | Диагностика и виды лечения, связанные с ингибиторами her3 |
| US9980942B2 (en) | 2012-05-02 | 2018-05-29 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
| JP6998646B2 (ja) | 2012-11-30 | 2022-02-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定 |
| EP3134436A4 (en) * | 2014-04-25 | 2017-12-27 | Memorial Sloan Kettering Cancer Center | Treatment of h-ras-driven tumors |
| US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
| WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
| EP4013402B1 (en) | 2019-08-16 | 2024-11-06 | Children's Hospital Medical Center | Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty |
| WO2023079320A1 (en) | 2021-11-02 | 2023-05-11 | Semmelweis Egyetem | Farnesyl-transferase inhibitors and kras inhibitors for treating kras mutant cancers |
| CN120053663B (zh) * | 2024-04-15 | 2025-12-12 | 天津医科大学 | Sp/klf转录因子抑制剂与去乙酰化酶抑制剂组合的制药用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2546577B2 (de) | 1975-10-17 | 1981-04-02 | Sandoz-Patent-GmbH, 7850 Lörrach | Feste Stoffe aus Polyvinylpyrrolidon und Ergotalkaloiden |
| EP0214092A1 (en) | 1985-08-08 | 1987-03-11 | Ciba-Geigy Ag | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone |
| US4764378A (en) | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
| US5089496A (en) | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| US4826853A (en) | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| CA1341044C (en) | 1988-04-28 | 2000-07-04 | Frank J. Villani | Benzopyrido piperidine, piperidylidene and peperazine compounds, compositions, methods of manufacture and methods of use |
| US5393890A (en) | 1988-06-02 | 1995-02-28 | Ajinomoto Co., Inc. | Piperidine derivatives and hypotensives containing the same |
| DE3830353A1 (de) | 1988-09-07 | 1990-03-15 | Basf Ag | Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen |
| DE69120430D1 (de) | 1990-12-18 | 1996-07-25 | Wellcome Found | Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen |
| JPH07505394A (ja) | 1992-03-27 | 1995-06-15 | シェリング・コーポレーション | 橋渡しビスアリールカルビノール誘導体，組成物および使用法 |
| US5512293A (en) | 1992-07-23 | 1996-04-30 | Alza Corporation | Oral sustained release drug delivery device |
| FR2698560B1 (fr) | 1992-11-30 | 1995-02-03 | Virbac Laboratoires | Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications. |
| SG48750A1 (en) | 1993-10-15 | 1998-05-18 | Schering Corp | Tricyclic carbonate compounds useful for inhabition of g-protein function for treatment of proliferative diseases |
| US5661152A (en) | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| IL111235A (en) | 1993-10-15 | 2001-03-19 | Schering Plough Corp | Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them |
| US5721236A (en) | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5719148A (en) | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| US5464840A (en) | 1993-12-06 | 1995-11-07 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
| US5523095A (en) | 1993-12-15 | 1996-06-04 | Eastman Chemical Company | Controlled release matrix system using cellulose acetate/polyvinylpyrrolidone blends |
| JP3893439B2 (ja) | 1994-12-19 | 2007-03-14 | 第一製薬株式会社 | 徐放性粒状製剤およびその製造方法 |
| US5700806A (en) | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5684013A (en) | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| IL117798A (en) | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| US5712280A (en) | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| WO1997005902A1 (fr) | 1995-08-09 | 1997-02-20 | Banyu Pharmaceutical Co., Ltd. | Composition medicinale |
| US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| CZ292791B6 (cs) | 1995-12-22 | 2003-12-17 | Schering Corporation | Tricyklické amidy, které se používají pro inhibici G-proteinové funkce a k léčení proliferativních onemocnění |
| JP2000504023A (ja) | 1996-04-03 | 2000-04-04 | メルク エンド カンパニー インコーポレーテッド | 癌治療方法 |
| JP2000508661A (ja) | 1996-04-15 | 2000-07-11 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 放射線および化学療法に対する細胞の感作 |
| WO1997038664A2 (en) | 1996-04-18 | 1997-10-23 | Merck & Co., Inc. | A method of treating cancer |
| EP0934270A1 (en) | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
| US5972381A (en) | 1996-06-28 | 1999-10-26 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| WO1998000113A1 (en) | 1996-06-28 | 1998-01-08 | Schering Corporation | Solid solution of an antifungal agent with enhanced bioavailability |
| US5945429A (en) | 1996-09-13 | 1999-08-31 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US5985879A (en) | 1996-09-13 | 1999-11-16 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| ES2234036T3 (es) | 1996-09-13 | 2005-06-16 | Schering Corporation | Compuestos utiles para inhibir la farnesil-protein-transferasa. |
| US5958890A (en) | 1996-09-13 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US6071907A (en) | 1996-09-13 | 2000-06-06 | Schering Corporation | Tricyclic compounds useful as FPT inhibitors |
| US6040305A (en) | 1996-09-13 | 2000-03-21 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
| US5861395A (en) | 1996-09-13 | 1999-01-19 | Schering Corporation | Compounds useful for inhibition of farnesyl proteins transferase |
| US5965570A (en) | 1996-09-13 | 1999-10-12 | Schering Corporation | Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase |
| US6030982A (en) | 1996-09-13 | 2000-02-29 | Schering Corporationm | Compounds useful for inhibition of farnesyl protein transferase |
| HUP0004326A3 (en) | 1997-02-18 | 2003-07-28 | Canji Inc San Diego | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
| US5852034A (en) | 1997-06-17 | 1998-12-22 | Schering Corporation | Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors |
| US5939416A (en) | 1997-06-17 | 1999-08-17 | Schering Corporation | Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors |
| US5925639A (en) | 1997-06-17 | 1999-07-20 | Schering Corporation | Keto amide derivatives useful as farnesyl protein transferase inhibitors |
| US5877177A (en) | 1997-06-17 | 1999-03-02 | Schering Corporation | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| US5958940A (en) | 1997-09-11 | 1999-09-28 | Schering Corporation | Tricyclic compounds useful as inhibitors of farnesyl-protein transferase |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AU761994C (en) | 1997-12-22 | 2004-01-08 | Merck Sharp & Dohme Corp. | Molecular dispersion composition with enhanced bioavailability |
-
1999
- 1999-04-09 US US09/289,255 patent/US6316462B1/en not_active Expired - Fee Related
-
2000
- 2000-04-06 WO PCT/US2000/009124 patent/WO2000061145A1/en not_active Ceased
- 2000-04-06 EP EP00921765A patent/EP1165078B1/en not_active Expired - Lifetime
- 2000-04-06 HK HK02100132.7A patent/HK1038512B/en not_active IP Right Cessation
- 2000-04-06 MX MXPA01010211A patent/MXPA01010211A/es active IP Right Grant
- 2000-04-06 BR BR0009670-9A patent/BR0009670A/pt not_active IP Right Cessation
- 2000-04-06 PT PT00921765T patent/PT1165078E/pt unknown
- 2000-04-06 CN CNB008085293A patent/CN100421661C/zh not_active Expired - Fee Related
- 2000-04-06 CA CA002364675A patent/CA2364675A1/en not_active Abandoned
- 2000-04-06 DE DE60032226T patent/DE60032226T2/de not_active Expired - Lifetime
- 2000-04-06 AR ARP000101576A patent/AR023400A1/es unknown
- 2000-04-06 TW TW089106323A patent/TWI255184B/zh not_active IP Right Cessation
- 2000-04-06 AU AU42041/00A patent/AU783177B2/en not_active Ceased
- 2000-04-06 ES ES00921765T patent/ES2275505T3/es not_active Expired - Lifetime
- 2000-04-06 AT AT00921765T patent/ATE347360T1/de not_active IP Right Cessation
- 2000-04-06 DK DK00921765T patent/DK1165078T3/da active
- 2000-04-06 JP JP2000610478A patent/JP2003529540A/ja active Pending
- 2000-04-06 HU HU0200773A patent/HUP0200773A3/hu unknown
- 2000-04-06 NZ NZ514628A patent/NZ514628A/xx not_active IP Right Cessation
- 2000-04-07 MY MYPI20001455A patent/MY120841A/en unknown
- 2000-04-07 PE PE2000000317A patent/PE20010025A1/es not_active Application Discontinuation
-
2001
- 2001-10-08 NO NO20014897A patent/NO329133B1/no not_active IP Right Cessation
- 2001-10-08 ZA ZA200108258A patent/ZA200108258B/xx unknown
-
2007
- 2007-03-01 CY CY20071100296T patent/CY1107545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1165078A1 (en) | 2002-01-02 |
| MY120841A (en) | 2005-11-30 |
| NZ514628A (en) | 2004-01-30 |
| ATE347360T1 (de) | 2006-12-15 |
| HUP0200773A2 (hu) | 2002-07-29 |
| HUP0200773A3 (en) | 2003-04-28 |
| NO20014897D0 (no) | 2001-10-08 |
| HK1038512B (en) | 2007-04-27 |
| JP2003529540A (ja) | 2003-10-07 |
| CN1364084A (zh) | 2002-08-14 |
| CA2364675A1 (en) | 2000-10-19 |
| DE60032226T2 (de) | 2007-10-11 |
| AR023400A1 (es) | 2002-09-04 |
| CN100421661C (zh) | 2008-10-01 |
| CY1107545T1 (el) | 2013-03-13 |
| PT1165078E (pt) | 2007-02-28 |
| DK1165078T3 (da) | 2007-04-16 |
| US6316462B1 (en) | 2001-11-13 |
| ES2275505T3 (es) | 2007-06-16 |
| WO2000061145A1 (en) | 2000-10-19 |
| DE60032226D1 (de) | 2007-01-18 |
| EP1165078B1 (en) | 2006-12-06 |
| BR0009670A (pt) | 2002-01-15 |
| MXPA01010211A (es) | 2002-09-18 |
| AU783177B2 (en) | 2005-09-29 |
| ZA200108258B (en) | 2003-03-26 |
| NO20014897L (no) | 2001-12-10 |
| TWI255184B (en) | 2006-05-21 |
| NO329133B1 (no) | 2010-08-30 |
| HK1038512A1 (en) | 2002-03-22 |
| AU4204100A (en) | 2000-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0108394A (pt) | Inibidores de cinase de proteìna de 2-indolinona de pirrol substituìdo | |
| MX9303158A (es) | Derivados de aminoquinolona substituidos con grupoarilo o con un grupo heterociclico aromatico; y agente anti-vih. | |
| AR069788A1 (es) | Formulacion de anticuerpo anti- cd20 humano y usos de la misma | |
| DE60143517D1 (de) | Wiederherstellung der gelenken mit mesenchymalen stammzellen | |
| PT845991E (pt) | Utilizacao de difosfonatos substituidos com fenol como agentes anti-neoplasicos | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| BR0007527B1 (pt) | fenilfenantridinas com atividade inibitària de pde-iv, seu uso, bem como medicamento compreendendo as mesmas. | |
| PA8504401A1 (es) | Compuestos farmaceuticamente activos | |
| HN1998000143A (es) | Tetrahidronaftalenos substituidos y compuestos analogos. | |
| ES2074867T3 (es) | Derivados de quinazolina para potenciar la actividad antitumoral. | |
| DE69937888D1 (de) | Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen | |
| ES2108125T3 (es) | Aporte in vivo de factores activos por implantes de celulas cultivadas conjuntamente. | |
| TR200002191T2 (tr) | Potasyum kanal önleyicileri | |
| ES2066806T3 (es) | Uso de la adenosina 5'-fosfato para el tratamiento de caquexia de cancer. | |
| ES8606450A1 (es) | Un procedimiento de preparar un nuevo compuesto con un grupopiridiniotriazinilo y un grupo vinilsulfone | |
| TR200103460T2 (tr) | 5-Fenil-pirimidin türevleri | |
| DE60033918D1 (de) | Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung | |
| AR018162A1 (es) | Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica | |
| BR0115121A (pt) | Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas | |
| ES2174603T3 (es) | Implante oseo. | |
| ATE402168T1 (de) | Heterocyclische topoisomerase toxine | |
| PT1147088E (pt) | 6-arilfenantridinas com actividade inibitoria da pde-iv | |
| ATE295352T1 (de) | Phenanthridine-n-oxide mit pde-iv hemmender wirkung | |
| AR044193A1 (es) | Compuesto de 1,2,4-triazol-5-ona, composicion farmaceutica que lo comprende, su uso para prepararla y kit que comprende dicho compuesto | |
| ES2160726T3 (es) | Derivados de piperazin-2,5-diona como moduladores de resistencia a multiples farmacos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |